Podcast
MSL Talk: Tom Caravela, Mitchell D’Rozario
Finding Success as a Rare Diseases MSL
Summary
In this episode, Giovanni Passiatore delves into the complexities of working in the rare diseases arena as an MSL. Giovanni shares his extensive background and provides insights into the unique challenges faced in this field, including strategies for effective territory coverage and engaging with key opinion leaders. He highlights the critical role of patient identification and the emerging importance of patient diagnosis liaisons. Giovanni offers essential advice for aspiring MSLs, emphasizing the significance of humility, relationship-building, and business acumen. The episode wraps up with a focus on the resilience required for success in the MSL role and appreciation for the audience's engagement.
My guest today is Giovanni Passiatore, Head of US MSLs at Chiesi Rare Disease and he shares insights on how to find success as a Rare Diseases MSL
Giovanni discusses…
👉 What the industry considers “Rare Diseases” as a category
👉 Challenges Rare Diseases Medical Affairs/MSL teams face
👉 How the medical affairs strategy differs for a Rare Diseases company
👉 How metrics and KPIs may differ for Rare Disease MSLs
👉 Recommendations for Rare Disease MSLs to find success and become high performers in their territory
👉 What he looks for when hiring Rare Diseases MSLs
rare diseases MSL, medical science liaison challenges, key opinion leaders engagement, patient diagnosis liaisons, rare disease territory coverage
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Mitchell D’Rozario
Article
Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
Article
Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
Article
Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
Article
iNIZIO
Transforming oncology: Five frontiers driving progress in cancer care
Article
iNIZIO